BACKGROUND AND OBJECTIVES: Vascular endothelial growth factor (VEGF) is known as an important factor in the growth and metastasis of cancer cells. In 2001, a novel angiogenesis factor, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was cloned. In this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants. METHODS: We determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses. RESULTS: The expression of EG-VEGF mRNA was positive in 31 cancers and negative in 82 cancers. We found that compared with the negative expression of the EG-VEGF gene, its positive expression was more frequently associated with hematogenous metastasis, and was associated with a poorer survival rate. In addition, EG-VEGF transfectants showed a higher degree of in vitro tubular formation than control cells. CONCLUSIONS: We speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor. EG-VEGF molecule-targeted therapy has the potential for improving survival rates.
BACKGROUND AND OBJECTIVES:Vascular endothelial growth factor (VEGF) is known as an important factor in the growth and metastasis of cancer cells. In 2001, a novel angiogenesis factor, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was cloned. In this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants. METHODS: We determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses. RESULTS: The expression of EG-VEGF mRNA was positive in 31 cancers and negative in 82 cancers. We found that compared with the negative expression of the EG-VEGF gene, its positive expression was more frequently associated with hematogenous metastasis, and was associated with a poorer survival rate. In addition, EG-VEGF transfectants showed a higher degree of in vitro tubular formation than control cells. CONCLUSIONS: We speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor. EG-VEGF molecule-targeted therapy has the potential for improving survival rates.
Authors: Dorothee Heck; Sebastian Wortmann; Luitgard Kraus; Cristina L Ronchi; Richard O Sinnott; Martin Fassnacht; Silviu Sbiera Journal: Horm Cancer Date: 2015-12 Impact factor: 3.869
Authors: Ana Silvia Corlan; Anca Maria Cîmpean; Adriana-Andreea Jitariu; Eugen Melnic; Marius Raica Journal: Int J Endocrinol Date: 2017-03-12 Impact factor: 3.257
Authors: Carolina Torres; Ana Linares; Maria José Alejandre; Rogelio J Palomino-Morales; Octavio Caba; Jose Prados; Antonia Aránega; Juan R Delgado; Antonio Irigoyen; Joaquina Martínez-Galán; Francisco M Ortuño; Ignacio Rojas; Sonia Perales Journal: Biomed Res Int Date: 2015-08-04 Impact factor: 3.411